316 related articles for article (PubMed ID: 2471782)
21. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites.
Xie QC; McCahon D; Crowther JR; Belsham GJ; McCullough KC
J Gen Virol; 1987 Jun; 68 ( Pt 6)():1637-47. PubMed ID: 2438378
[TBL] [Abstract][Full Text] [Related]
22. The main antigenic determinant detected by neutralizing monoclonal antibodies on the intact foot-and-mouth disease virus particle is absent from isolated VPI.
Meloen RH; Briaire J; Woortmeyer RJ; van Zaane D
J Gen Virol; 1983 May; 64(Pt 5):1193-8. PubMed ID: 6188800
[TBL] [Abstract][Full Text] [Related]
23. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.
Mayr GA; Chinsangaram J; Grubman MJ
Virology; 1999 Oct; 263(2):496-506. PubMed ID: 10544121
[TBL] [Abstract][Full Text] [Related]
24. Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle.
Gebauer F; de la Torre JC; Gomes I; Mateu MG; Barahona H; Tiraboschi B; Bergmann I; de Mello PA; Domingo E
J Virol; 1988 Jun; 62(6):2041-9. PubMed ID: 2835508
[TBL] [Abstract][Full Text] [Related]
25. Antibodies raised in a natural host and monoclonal antibodies recognize similar antigenic features of foot-and-mouth disease virus.
Mateu MG; Andreu D; Domingo E
Virology; 1995 Jun; 210(1):120-7. PubMed ID: 7793064
[TBL] [Abstract][Full Text] [Related]
26. Antigenic sites on foot-and-mouth disease virus type A10.
Thomas AA; Woortmeijer RJ; Puijk W; Barteling SJ
J Virol; 1988 Aug; 62(8):2782-9. PubMed ID: 2455819
[TBL] [Abstract][Full Text] [Related]
27. Antigenic variation among foot-and-mouth disease virus type A field isolates of 1997-1999 from Iran.
Marquardt O; Freiberg B
Vet Microbiol; 2000 Jun; 74(4):377-86. PubMed ID: 10831859
[TBL] [Abstract][Full Text] [Related]
28. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants.
Crowther JR; Farias S; Carpenter WC; Samuel AR
J Gen Virol; 1993 Aug; 74 ( Pt 8)():1547-53. PubMed ID: 8393912
[TBL] [Abstract][Full Text] [Related]
29. Antigenic properties and population stability of a foot-and-mouth disease virus with an altered Arg-Gly-Asp receptor-recognition motif.
Ruiz-Jarabo CM; Sevilla N; Dávila M; Gómez-Mariano G; Baranowski E; Domingo E
J Gen Virol; 1999 Aug; 80 ( Pt 8)():1899-1909. PubMed ID: 10466785
[TBL] [Abstract][Full Text] [Related]
30. Identification of virus neutralizing epitopes on naturally occurring variants of type A12 foot-and-mouth disease virus.
Moore DM; Vakharia VN; Morgan DO
Virus Res; 1989 Dec; 14(4):281-95. PubMed ID: 2483013
[TBL] [Abstract][Full Text] [Related]
31. Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus.
Parry N; Fox G; Rowlands D; Brown F; Fry E; Acharya R; Logan D; Stuart D
Nature; 1990 Oct; 347(6293):569-72. PubMed ID: 1699132
[TBL] [Abstract][Full Text] [Related]
32. Genetic and antigenic analysis of type A foot-and-mouth disease viruses isolated in India during 1987-1996.
Nayak B; Pattnaik B; Tosh C; Sanyal A; Hemadri D; Patil SS; Venkataramanan R
Acta Virol; 2001 Feb; 45(1):13-21. PubMed ID: 11394573
[TBL] [Abstract][Full Text] [Related]
33. The structure and antigenicity of a type C foot-and-mouth disease virus.
Lea S; Hernández J; Blakemore W; Brocchi E; Curry S; Domingo E; Fry E; Abu-Ghazaleh R; King A; Newman J
Structure; 1994 Feb; 2(2):123-39. PubMed ID: 8081743
[TBL] [Abstract][Full Text] [Related]
34. Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity.
Curry S; Fry E; Blakemore W; Abu-Ghazaleh R; Jackson T; King A; Lea S; Newman J; Rowlands D; Stuart D
Structure; 1996 Feb; 4(2):135-45. PubMed ID: 8805520
[TBL] [Abstract][Full Text] [Related]
35. Antigenic site variation in foot-and-mouth disease virus serotype O grown under vaccinal serum antibodies in vitro.
Sarangi LN; Mohapatra JK; Subramaniam S; Sanyal A; Pattnaik B
Virus Res; 2013 Sep; 176(1-2):273-9. PubMed ID: 23850868
[TBL] [Abstract][Full Text] [Related]
36. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.
Stave JW; Card JL; Morgan DO; Vakharia VN
Virology; 1988 Jan; 162(1):21-9. PubMed ID: 2827379
[TBL] [Abstract][Full Text] [Related]
37. Production and characterization of two serotype independent monoclonal antibodies against foot-and-mouth disease virus.
Yang M; Clavijo A; Suarez-Banmann R; Avalo R
Vet Immunol Immunopathol; 2007 Jan; 115(1-2):126-34. PubMed ID: 17109972
[TBL] [Abstract][Full Text] [Related]
38. Genetic and immunogenic variations among closely related isolates of foot-and-mouth disease virus.
Martinez MA; Carrillo C; Plana J; Mascarella R; Bergada J; Palma EL; Domingo E; Sobrino F
Gene; 1988; 62(1):75-84. PubMed ID: 2453395
[TBL] [Abstract][Full Text] [Related]
39. A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance.
Borrego B; Camarero JA; Mateu MG; Domingo E
Viral Immunol; 1995; 8(1):11-8. PubMed ID: 8546800
[TBL] [Abstract][Full Text] [Related]
40. Genetic and antigenic variance of foot-and-mouth disease virus type Asia1.
Marquardt O; Rahman MM; Freiberg B
Arch Virol; 2000; 145(1):149-57. PubMed ID: 10664412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
